Have a personal or library account? Click to login
Variability of Steroid Prescription for COVID-19 Associated Pneumonia in Real-Life, Non-Trial Settings Cover

Figures & Tables

Fig. 1

Length of stay in hospital (LOS)

Fig. 2

Days of stay in ICU

Sample Characteristics Continuous Variables

Total N=235No steroids N=23Low dose N=42Medium dose N=23High dose N=151
Continuous variablesMedianIQRMedianIQRMedianIQRMedianIQRMedianIQR
Demographic recorded
Age(years)4942-574739-605045-585047-524942-56
BMI (Kg/)2723-302624-322621-312421-312824-32
Days turn test negative
5
0-16
2
0-10
0
0-9
8
3-23
7
0-18
Inpatient clinical data on admission
Oxygen (ml)
10
0-15
4
0-10
15
4-15
15
8.5-15
15
0.05-10
Laboratory parameters
Ferritin (ng/ml)1230483-1895468120-1520620214-18041204532-7501385750-1986
D-Dimer (ng/ml)1.110.52-3.800.610.29-3.021.170.58-2.23.91.01-8.991.110.58-3.43
Procalcitonin (ng/ml)0.350.14-1.1680.270.1-2.260.210.1-1.230.310.15-0.980.370.16-1.10
CRP (mg/L)129.575.2-215.8810464.8-21613373.4-1619859.6-15613784.5-225
Creatinine (mg/dl)0.90.8-1.20.90.7-1.280.80.7-1.60.90.78-1.310.8-1.2
CPK (units/L)196.569.25-626.5012017.8-43916452-410310141-60921886-689
ABG PH7.377.25-7.437.350-7.437.37.19-7.387.407.35-7.447.377.28-7.43
PCo2 (Torr)35.829.93-45.58300-36.437.132.6-48.635.231.7-42.93831.5-48.3
PO2 (Torr)61.344.30-84.9548.70-88.76447-7361.845.5-756247.4-85.7
Lactate1.71.2-2.51.350.23-2.282.41.4-6.31.91.37-3.471.71.2-2.3
Bicarbonate (mEq/L)21.5518.8-242014.2-22.520.716.3-23.921.419.7-23.622.119.5-24.4
Magnesium (mg/dl)2.031.84-2.242.011.72-2.161.941.7-2.242.091.87-2.392.041.90-2.26
Platelets (/microliter)196.5150.25-260.5206158-252214141-299164126-253197152-262
WBC (/microliter)
7.9
6.03-10.7
7.9
5.9-10.8
8.1
6.3-13
7.15
6.15-9.85
7.9
6-10.7
Severity of illness
APACHE 2 score
16
12-20
15.5
2.25-24.5
16
13-22
18.5
13-24.2
16
12-19
Variable of interest
Days on Mech. Vent.104-2040-8.7521-9157.75-23148-23
LOSICU (days)124-22.7540-8.7521-9178.75-23.81810-30.5
LOS in hospital (days)188-32106.25-18.852-122813.8-49.52212.5-35.5

Sample characteristics (categorical variables)

Categorical variablesTotal Sample N 235No steroids N 23Low dose N 42Medium dose N 23High dose N 151
1= variable present
0
1
0
1
0
1
0
1
0
1
Demographic recorded
Gender (F=0, M=1) (%)13873.8172.97.61.37.14.655.5
Presence of symptoms
cough20806.714.32.18.42.55.98.851.3
fever9912.518.51.39.20.48555
dyspnea20807.613.41.39.21.76.79.750.4
Gastric complaints
88
12
18.5
2.5
8
2.5
7.1
1.3
54.6
5.5
Comorbidities
diabetes574310.110.97.13.45.5334.525.6
hypertension752515.55.56.34.253.448.311.8
coronary disease93718.52.58.81.780.4582.1
renal failure881218.12.99.70.86.71.753.46.7
dialysis
93
7
19.7
1.2
9.7
0.8
7.6
0.8
56.3
3.8
Inpatient clinical data on admission
Immunosuppressed96420.60.410.10.47.11.358.41.7
Fever14864.216.81.78.81.37.16.753.4
Tachycardia (pulse>100)21795.515.52.18.42.55.911.348.7
Hypotension on admission (MAP<60 mm of Hg)505010.910.16.73.84.24.228.231.9
Hypoxia on admission13875.915.10.89.70.87.65.954.2
Mechanical Ventilation15857.113.92.580.484.655.5
Vasopressors217910.110.93.47.10.87.66.753.4
Dialysis on admission
70
30
16.4
4.6
8.4
2.1
5
3.4
39.9
20.2
Clinical parameters
Lymphopenia (≤ 1100 cells/μL)445612.28.87.13.42.95.521.838.2
Bacterial infection49511659.21.33.4520.239.9
Bacteremia60408.12.99.70.85.52.926.933.2
Positive cultures455515.15.98.81.72.55.918.142
Arrhythmia
15
22
15.5
5.5
8.8
1.7
6.7
1.7
47.1
13
Associated treatment
Anticoagulants4962.918.1010.508.40.859.2
Gastro-intestinal prophylaxis (Proton pump inhibitors)
4
96
2.1
18.9
0.8
9.7
0
8.4
1.3
58.8
Therapeutic agent
Lopinavir/Ritonavir6943.417.61.39.20.481.358.8
Chloroquine12884.216.81.78.81.37.1555
Lopinavir/Ritonavir643616.84.26.34.24.63.836.123.9
Favipiravir208010.510.52.581.37.15.954.2
Tociluzimab841620.20.89.70.86.71.747.512.6
Plasmatherapy83172109.70.86.71.745.814.3
Tracheostomy871720.20.810.507.60.848.711.3
ECMO95521010.507.60.855.54.6
Surgeries96420.60.410.5080.456.73.4
Sedatives11896.714.31.78.80.482.557.6
Narcotics24769.711.31.78.82.16.310.549.6
Neuromuscular blocking agents15858.812.22.580.87.62.957.1
DOI: https://doi.org/10.2478/jccm-2022-0025 | Journal eISSN: 2393-1817 | Journal ISSN: 2393-1809
Language: English
Page range: 259 - 265
Submitted on: Sep 11, 2021
|
Accepted on: Sep 11, 2022
|
Published on: Nov 12, 2022
In partnership with: Paradigm Publishing Services
Publication frequency: 4 issues per year

© 2022 Rashid Nadeem, Islam Bon, Doaa Algohary, Mohd Kafeel Khan, Nilesh Gundawar, Mohammed Abdullah, Ekta Sharma, Moatz Galal Elzeiny, Mayada Mahmoud, Ashraf Elhoufi, Yusra Omar Alshaikh Sayed Ahmed, Gloria Gheno, Maged Talaat Salama Khalil, Tamseela Hussain, published by University of Medicine, Pharmacy, Science and Technology of Targu Mures
This work is licensed under the Creative Commons Attribution 4.0 License.